Long-term study of ATTR-CM patients on vutrisiran or other approved therapies
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study observes people with ATTR-CM (a heart condition caused by a protein called transthyretin) who are starting treatment with vutrisiran or another approved therapy. It aims to understand how the disease progresses and how treatments work in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ATTR-CM (transthyretin amyloid cardiomyopathy, a type of heart condition).
- You are planning to start or have started treatment with vutrisiran or another approved ATTR-CM therapy.
- You are not currently enrolled in a different clinical trial that involves an experimental treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called vutrisiran for people with a condition called transthyretin amyloidosis that affects the heart. It is for patients who have already been in certain earlier studies of patisiran or vutrisiran.
This study looks at how a heart medication (tafamidis) affects amyloid protein levels in the blood over time. It may help doctors understand how well the treatment works for people with a specific type of heart disease caused by amyloid buildup (ATTR-CM).
This study follows patients with ATTR amyloidosis over time to understand how the disease affects them. It does not test a new treatment—instead, it asks you to fill out questionnaires about your health and symptoms to help doctors learn more about the condition.
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
This registry collects information from people with ATTR-CM, a condition where abnormal protein builds up in the heart. By joining, you help researchers learn more about the disease and improve future care.
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
Hear when a new Transthyretin Amyloidosis With Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.